Pros
Really good, dedicated employees; all motivated and driven to help people with diabetes. Stock has skyrocketed, so if you have equity, you are doing well. New office is nice.
Cons
The positive stock performance masks some real issues here. Lack of leadership, across the organization, abounds, as employees do jobs they were never meant to do, in the hopes of getting promoted into the role they are already doing. VPs and SVPs don't show up to meetings and ignore emails. Everyone just accepts it and moves on by trying to find someone else to weigh-in. Overall the leadership team is weak. A few bright spots, but mostly just former retirees hanging out in their own "executive suite" and collecting fat stock option checks. From commercial, clinical, legal, R and D and others, the team is basically rudderless and undirected, as roles have expanded, but the structure and actual, stated responsibilities remain the same. Outside onlookers don't notice, because the stock has continued to soar, but it masks the reality that the company is floundering; not hiring people who need to be hired, refusing to give clear direction to people on their actual jobs, and way behind its competitors in terms of innovation. It's sad because the previous CEO would never have allowed this to go on and he left the company in a great position.
